Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

[1]  C. Bloomfield,et al.  Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Z. Estrov,et al.  A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities. , 2012, Clinical Lymphoma, Myeloma & Leukemia.

[3]  J. Liesveld,et al.  Proteasome Inhibition in Myelodysplastic Syndromes and Acute Myelogenous Leukemia Cell Lines , 2011, Cancer Investigation.

[4]  F. Mandelli,et al.  Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes. , 2011, Leukemia research.

[5]  M. Grever,et al.  Dose escalation of lenalidomide in relapsed or refractory acute leukemias. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P. Woll,et al.  Persistent malignant stem cells in del(5q) myelodysplasia in remission. , 2010, The New England journal of medicine.

[7]  D. Esseltine,et al.  Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. , 2010, Blood.

[8]  D. Esseltine,et al.  Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Neuberg,et al.  Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia , 2008, Clinical Cancer Research.

[10]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[11]  G. Kroemer,et al.  NF-κB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome , 2005 .

[12]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Howard,et al.  Preferential induction of apoptosis for primary human leukemic stem cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[14]  D. Howard,et al.  Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. , 2001, Blood.

[15]  R. Latagliata,et al.  Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study , 2012, Annals of Hematology.

[16]  R. Vij,et al.  A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia , 2011 .

[17]  M. Gordon.  Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion , 2008 .

[18]  J. Reeves,et al.  Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. , 2008, Blood.

[19]  J. Reeves,et al.  Phase 2 study of lenalidomide in transfusion-dependent , low-risk , and intermediate-1 – risk myelodysplastic syndromes with karyotypes other than deletion 5 q , 2007 .

[20]  G. Kroemer,et al.  NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. , 2006, Blood.